{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T13:39:39Z","timestamp":1777642779757,"version":"3.51.4"},"reference-count":43,"publisher":"Springer Science and Business Media LLC","issue":"9","license":[{"start":{"date-parts":[[2013,4,2]],"date-time":"2013-04-02T00:00:00Z","timestamp":1364860800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2013,4,2]],"date-time":"2013-04-02T00:00:00Z","timestamp":1364860800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Leukemia"],"published-print":{"date-parts":[[2013,9]]},"DOI":"10.1038\/leu.2013.95","type":"journal-article","created":{"date-parts":[[2013,4,2]],"date-time":"2013-04-02T02:38:05Z","timestamp":1364870285000},"page":"1902-1909","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":182,"title":["Oral lenalidomide with rituximab in relapsed or refractory diffuse large cell, follicular and transformed lymphoma: a phase II clinical trial"],"prefix":"10.1038","volume":"27","author":[{"given":"M","family":"Wang","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"N","family":"Fowler","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"N","family":"Wagner-Bartak","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"L","family":"Feng","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J","family":"Romaguera","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"S S","family":"Neelapu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"F","family":"Hagemeister","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M","family":"Fanale","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Y","family":"Oki","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"B","family":"Pro","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J","family":"Shah","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"S","family":"Thomas","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A","family":"Younes","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"C","family":"Hosing","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"L","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"K J","family":"Newberry","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M","family":"Desai","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"N","family":"Cheng","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M","family":"Badillo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M","family":"Bejarano","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Y","family":"Chen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"K H","family":"Young","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"R","family":"Champlin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"L","family":"Kwak","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"L","family":"Fayad","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2013,4,2]]},"reference":[{"key":"BFleu201395_CR1","doi-asserted-by":"publisher","first-page":"695","DOI":"10.1182\/blood-2006-11-051672","volume":"110","author":"LM Morton","year":"2007","unstructured":"Morton LM, Turner JJ, Cerhan JR, Linet MS, Treseler PA, Clarke CA et al. Proposed classification of lymphoid neoplasms for epidemiologic research from the Pathology Working Group of the International Lymphoma Epidemiology Consortium (InterLymph). Blood 2007; 110: 695\u2013708.","journal-title":"Blood"},{"key":"BFleu201395_CR2","unstructured":"Swerdlow SH, Campo E, Harris NL, Jaffe ES, Pileri SA, Stein H et alIn, 2008 Swerdlow SH, Campo E, Harris NL, Jaffe ES, Pileri S, Stein H, Thiele J, Vardiman J (eds). WHO Classification of Tumours of Haematopoietic and Lymphoid Systems, Follicular Lymphoma 4th edn IARC: Lyon, pp 220\u2013228."},{"key":"BFleu201395_CR3","doi-asserted-by":"publisher","first-page":"1654","DOI":"10.1200\/JCO.1997.15.4.1654","volume":"15","author":"D Wendum","year":"1997","unstructured":"Wendum D, Sebban C, Gaulard P, Coiffier B, Tilly H, Cazals D et al. Follicular large-cell lymphoma treated with intensive chemotherapy: an analysis of 89 cases included in the LNH87 trial and comparison with the outcome of diffuse large B-cell lymphoma. Groupe d\u2019Etude des Lymphomes de l\u2019Adulte. J Clin Oncol 1997; 15: 1654\u20131663.","journal-title":"J Clin Oncol"},{"key":"BFleu201395_CR4","doi-asserted-by":"publisher","first-page":"433","DOI":"10.1097\/CCO.0b013e3282c9ad78","volume":"19","author":"PJ Bierman","year":"2007","unstructured":"Bierman PJ . Natural history of follicular grade 3 non-Hodgkin's lymphoma. Curr Opin Oncol 2007; 19: 433\u2013437.","journal-title":"Curr Opin Oncol"},{"key":"BFleu201395_CR5","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1016\/S1470-2045(08)70002-0","volume":"9","author":"M Pfreundschuh","year":"2008","unstructured":"Pfreundschuh M, Schubert J, Ziepert M, Schmits R, Mohren M, Lengfelder E et al. Six versus eight cycles of bi-weekly CHOP-14 with or without rituximab in elderly patients with aggressive CD20+ B-cell lymphomas: a randomised controlled trial (RICOVER-60). Lancet Oncol 2008; 9: 105\u2013116.","journal-title":"Lancet Oncol"},{"key":"BFleu201395_CR6","doi-asserted-by":"publisher","first-page":"1013","DOI":"10.1016\/S1470-2045(11)70235-2","volume":"12","author":"M Pfreundschuh","year":"2011","unstructured":"Pfreundschuh M, Kuhnt E, Trumper L, Osterborg A, Trneny M, Shepherd L et al. CHOP-like chemotherapy with or without rituximab in young patients with good-prognosis diffuse large-B-cell lymphoma: 6-year results of an open-label randomised study of the MabThera International Trial (MInT) Group. Lancet Oncol 2011; 12: 1013\u20131022.","journal-title":"Lancet Oncol"},{"issue":"Suppl 2","key":"BFleu201395_CR7","doi-asserted-by":"publisher","first-page":"S57","DOI":"10.3816\/CLM.2007.s.034","volume":"8","author":"L Fayad","year":"2007","unstructured":"Fayad L, Thomas D, Romaguera J . Update of the M. D. Anderson Cancer Center experience with hyper-CVAD and rituximab for the treatment of mantle cell and Burkitt-type lymphomas. Clin Lymphoma Myeloma 2007; 8 (Suppl 2): S57\u2013S62.","journal-title":"Clin Lymphoma Myeloma"},{"key":"BFleu201395_CR8","doi-asserted-by":"publisher","first-page":"4952","DOI":"10.1200\/JCO.2007.15.3429","volume":"26","author":"PH Wiernik","year":"2008","unstructured":"Wiernik PH, Lossos IS, Tuscano JM, Justice G, Vose JM, Cole CE et al. Lenalidomide monotherapy in relapsed or refractory aggressive non-Hodgkin's lymphoma. J Clin Oncol 2008; 26: 4952\u20134957.","journal-title":"J Clin Oncol"},{"key":"BFleu201395_CR9","doi-asserted-by":"publisher","first-page":"5404","DOI":"10.1200\/JCO.2008.21.1169","volume":"27","author":"TE Witzig","year":"2009","unstructured":"Witzig TE, Wiernik PH, Moore T, Reeder C, Cole C, Justice G et al. Lenalidomide oral monotherapy produces durable responses in relapsed or refractory indolent non-Hodgkin's Lymphoma. J Clin Oncol 2009; 27: 5404\u20135409.","journal-title":"J Clin Oncol"},{"key":"BFleu201395_CR10","doi-asserted-by":"publisher","first-page":"1622","DOI":"10.1093\/annonc\/mdq626","volume":"22","author":"TE Witzig","year":"2011","unstructured":"Witzig TE, Vose JM, Zinzani PL, Reeder CB, Buckstein R, Polikoff JA et al. An international phase II trial of single-agent lenalidomide for relapsed or refractory aggressive B-cell non-Hodgkin's lymphoma. Ann Oncol 2011; 22: 1622\u20131627.","journal-title":"Ann Oncol"},{"key":"BFleu201395_CR11","doi-asserted-by":"publisher","first-page":"4713","DOI":"10.1182\/blood-2009-04-217687","volume":"114","author":"AG Ramsay","year":"2009","unstructured":"Ramsay AG, Clear AJ, Kelly G, Fatah R, Matthews J, Macdougall F et al. Follicular lymphoma cells induce T-cell immunologic synapse dysfunction that can be repaired with lenalidomide: implications for the tumor microenvironment and immunotherapy. Blood 2009; 114: 4713\u20134720.","journal-title":"Blood"},{"key":"BFleu201395_CR12","doi-asserted-by":"publisher","first-page":"5984","DOI":"10.1158\/1078-0432.CCR-05-0577","volume":"11","author":"FJ Hernandez-Ilizaliturri","year":"2005","unstructured":"Hernandez-Ilizaliturri FJ, Reddy N, Holkova B, Ottman E, Czuczman MS . Immunomodulatory drug CC-5013 or CC-4047 and rituximab enhance antitumor activity in a severe combined immunodeficient mouse lymphoma model. Clin Cancer Res 2005; 11: 5984\u20135992.","journal-title":"Clin Cancer Res"},{"key":"BFleu201395_CR13","doi-asserted-by":"publisher","first-page":"4650","DOI":"10.1158\/1078-0432.CCR-07-4405","volume":"14","author":"L Wu","year":"2008","unstructured":"Wu L, Adams M, Carter T, Chen R, Muller G, Stirling D et al. Lenalidomide enhances natural killer cell and monocyte-mediated antibody-dependent cellular cytotoxicity of rituximab-treated CD20+ tumor cells. Clin Cancer Res 2008; 14: 4650\u20134657.","journal-title":"Clin Cancer Res"},{"key":"BFleu201395_CR14","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1111\/j.1365-2141.2007.06841.x","volume":"140","author":"N Reddy","year":"2008","unstructured":"Reddy N, Hernandez-Ilizaliturri FJ, Deeb G, Roth M, Vaughn M, Knight J et al. Immunomodulatory drugs stimulate natural killer-cell function, alter cytokine production by dendritic cells, and inhibit angiogenesis enhancing the anti-tumour activity of rituximab in vivo. Br J Haematol 2008; 140: 36\u201345.","journal-title":"Br J Haematol"},{"key":"BFleu201395_CR15","doi-asserted-by":"publisher","first-page":"553","DOI":"10.1002\/ajh.21468","volume":"84","author":"L Zhang","year":"2009","unstructured":"Zhang L, Qian Z, Cai Z, Sun L, Wang H, Bartlett JB et al. Synergistic antitumor effects of lenalidomide and rituximab on mantle cell lymphoma in vitro and in vivo. Am J Hematol 2009; 84: 553\u2013559.","journal-title":"Am J Hematol"},{"key":"BFleu201395_CR16","doi-asserted-by":"publisher","first-page":"716","DOI":"10.1016\/S1470-2045(12)70200-0","volume":"13","author":"M Wang","year":"2012","unstructured":"Wang M, Fayad L, Wagner-Bartak N, Zhang L, Hagemeister F, Neelapu SS et al. Lenalidomide in combination with rituximab for patients with relapsed or refractory mantle-cell lymphoma: a phase 1\/2 clinical trial. Lancet Oncol 2012; 13: 716\u2013723.","journal-title":"Lancet Oncol"},{"key":"BFleu201395_CR17","doi-asserted-by":"publisher","first-page":"462","DOI":"10.1016\/j.clml.2011.02.001","volume":"11","author":"PL Zinzani","year":"2011","unstructured":"Zinzani PL, Pellegrini C, Gandolfi L, Stefoni V, Quirini F, Derenzini E et al. Combination of lenalidomide and rituximab in elderly patients with relapsed or refractory diffuse large B-cell lymphoma: a phase 2 trial. Clin Lymphoma Myeloma Leuk 2011; 11: 462\u2013466.","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"BFleu201395_CR18","doi-asserted-by":"publisher","first-page":"8030","DOI":"10.1200\/jco.2011.29.15_suppl.8030","volume":"29","author":"F Samaniego","year":"2011","unstructured":"Samaniego F, Hagemeister F, Mclaughlin P, Kwak LW, Romaguera J, Fanale MA et al. High response rates with lenalidomide plus rituximab for untreated indolent B-cell non-Hodgkin lymphoma, including those meeting GELF criteria. J Clin Oncol 2011; 29: 8030.","journal-title":"J Clin Oncol"},{"key":"BFleu201395_CR19","first-page":"8000","volume":"30","author":"J Leonard","year":"2012","unstructured":"Leonard J, Jung S-H, Johnson JL, Bartlett N, Blum KA, Cheson BD et al. CALGB 50401: A randomized trial of lenalidomide alone versus lenalidomide plus rituximab in patients with recurrent follicular lymphoma. ASCO Meeting Abstr 2012; 30: 8000.","journal-title":"ASCO Meeting Abstr"},{"key":"BFleu201395_CR20","doi-asserted-by":"publisher","first-page":"1244","DOI":"10.1200\/JCO.1999.17.4.1244","volume":"17","author":"BD Cheson","year":"1999","unstructured":"Cheson BD, Horning SJ, Coiffier B, Shipp MA, Fisher RI, Connors JM et al. Report of an international workshop to standardize response criteria for non-Hodgkin's lymphomas. NCI Sponsored International Working Group. J Clin Oncol 1999; 17: 1244.","journal-title":"J Clin Oncol"},{"key":"BFleu201395_CR21","doi-asserted-by":"publisher","first-page":"579","DOI":"10.1200\/JCO.2006.09.2403","volume":"25","author":"BD Cheson","year":"2007","unstructured":"Cheson BD, Pfistner B, Juweid ME, Gascoyne RD, Specht L, Horning SJ et al. Revised response criteria for malignant lymphoma. J Clin Oncol 2007; 25: 579\u2013586.","journal-title":"J Clin Oncol"},{"key":"BFleu201395_CR22","doi-asserted-by":"publisher","first-page":"2103","DOI":"10.1038\/leu.2012.83","volume":"26","author":"C Visco","year":"2012","unstructured":"Visco C, Li Y, Xu-Monette ZY, Miranda RN, Green TM, Tzankov A et al. Comprehensive gene expression profiling and immunohistochemical studies support application of immunophenotypic algorithm for molecular subtype classification in diffuse large B-cell lymphoma: a report from the International DLBCL Rituximab-CHOP Consortium Program Study. Leukemia 2012; 26: 2103\u20132113.","journal-title":"Leukemia"},{"key":"BFleu201395_CR23","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/0197-2456(89)90015-9","volume":"10","author":"R Simon","year":"1989","unstructured":"Simon R . Optimal two-stage designs for phase II clinical trials. Control Clin Trials 1989; 10: 1\u201310.","journal-title":"Control Clin Trials"},{"key":"BFleu201395_CR24","doi-asserted-by":"publisher","first-page":"4184","DOI":"10.1200\/JCO.2010.28.1618","volume":"28","author":"C Gisselbrecht","year":"2010","unstructured":"Gisselbrecht C, Glass B, Mounier N, Singh Gill D, Linch DC, Trneny M et al. Salvage regimens with autologous transplantation for relapsed large B-cell lymphoma in the rituximab era. J Clin Oncol 2010; 28: 4184\u20134190.","journal-title":"J Clin Oncol"},{"key":"BFleu201395_CR25","doi-asserted-by":"publisher","first-page":"1937","DOI":"10.1056\/NEJMoa012914","volume":"346","author":"A Rosenwald","year":"2002","unstructured":"Rosenwald A, Wright G, Chan WC, Connors JM, Campo E, Fisher RI et al. The use of molecular profiling to predict survival after chemotherapy for diffuse large-B-cell lymphoma. N Engl J Med 2002; 346: 1937\u20131947.","journal-title":"N Engl J Med"},{"key":"BFleu201395_CR26","doi-asserted-by":"publisher","first-page":"851","DOI":"10.1084\/jem.20031074","volume":"198","author":"A Rosenwald","year":"2003","unstructured":"Rosenwald A, Wright G, Leroy K, Yu X, Gaulard P, Gascoyne RD et al. Molecular diagnosis of primary mediastinal B cell lymphoma identifies a clinically favorable subgroup of diffuse large B cell lymphoma related to Hodgkin lymphoma. J Exp Med 2003; 198: 851\u2013862.","journal-title":"J Exp Med"},{"key":"BFleu201395_CR27","doi-asserted-by":"publisher","first-page":"503","DOI":"10.1038\/35000501","volume":"403","author":"AA Alizadeh","year":"2000","unstructured":"Alizadeh AA, Eisen MB, Davis RE, Ma C, Lossos IS, Rosenwald A et al. Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling. Nature 2000; 403: 503\u2013511.","journal-title":"Nature"},{"key":"BFleu201395_CR28","doi-asserted-by":"publisher","first-page":"3871","DOI":"10.1182\/blood-2003-06-1841","volume":"102","author":"KJ Savage","year":"2003","unstructured":"Savage KJ, Monti S, Kutok JL, Cattoretti G, Neuberg D, De Leval L et al. The molecular signature of mediastinal large B-cell lymphoma differs from that of other diffuse large B-cell lymphomas and shares features with classical Hodgkin lymphoma. Blood 2003; 102: 3871\u20133879.","journal-title":"Blood"},{"key":"BFleu201395_CR29","doi-asserted-by":"publisher","first-page":"13520","DOI":"10.1073\/pnas.0804295105","volume":"105","author":"G Lenz","year":"2008","unstructured":"Lenz G, Wright GW, Emre NC, Kohlhammer H, Dave SS, Davis RE et al. Molecular subtypes of diffuse large B-cell lymphoma arise by distinct genetic pathways. Proc Natl Acad Sci USA 2008; 105: 13520\u201313525.","journal-title":"Proc Natl Acad Sci USA"},{"key":"BFleu201395_CR30","doi-asserted-by":"publisher","first-page":"2313","DOI":"10.1056\/NEJMoa0802885","volume":"359","author":"G Lenz","year":"2008","unstructured":"Lenz G, Wright G, Dave SS, Xiao W, Powell J, Zhao H et al. Stromal gene signatures in large-B-cell lymphomas. N Engl J Med 2008; 359: 2313\u20132323.","journal-title":"N Engl J Med"},{"key":"BFleu201395_CR31","doi-asserted-by":"publisher","first-page":"4079","DOI":"10.1200\/JCO.2011.35.4423","volume":"29","author":"C Thieblemont","year":"2011","unstructured":"Thieblemont C, Briere J, Mounier N, Voelker HU, Cuccuini W, Hirchaud E et al. The germinal center\/activated B-cell subclassification has a prognostic impact for response to salvage therapy in relapsed\/refractory diffuse large B-cell lymphoma: a bio-CORAL study. J Clin Oncol 2011; 29: 4079\u20134087.","journal-title":"J Clin Oncol"},{"key":"BFleu201395_CR32","doi-asserted-by":"publisher","first-page":"5058","DOI":"10.1002\/cncr.26135","volume":"117","author":"FJ Hernandez-Ilizaliturri","year":"2011","unstructured":"Hernandez-Ilizaliturri FJ, Deeb G, Zinzani PL, Pileri SA, Malik F, Macon WR et al. Higher response to lenalidomide in relapsed\/refractory diffuse large B-cell lymphoma in nongerminal center B-cell-like than in germinal center B-cell-like phenotype. Cancer 2011; 117: 5058\u20135066.","journal-title":"Cancer"},{"issue":"1","key":"BFleu201395_CR33","doi-asserted-by":"publisher","first-page":"532","DOI":"10.1182\/asheducation-2009.1.532","volume":"2009","author":"S. H. Bernstein","year":"2009","unstructured":"Bernstein SH, Burack WR . The incidence, natural history, biology, and treatment of transformed lymphomas. Hematology Am Soc Hematol Educ Program 2009, 532\u2013541.","journal-title":"Hematology"},{"key":"BFleu201395_CR34","first-page":"154a","volume":"2006","author":"NM Reddy","year":"2006","unstructured":"Reddy NM, Hernandez-Ilizaliturri FJ, Czuczman MS . The use of the immunomodulatory drug, lenalidomide (Revlimid(R)) as a novel strategy to overcome acquired antibody resistance in rituximab-resistant non-Hodgkin's lymphoma (NHL) cell lines. AACR Meet Abstr 2006; 2006: 154a.","journal-title":"AACR Meet Abstr"},{"key":"BFleu201395_CR35","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1016\/S0140-6736(10)62175-7","volume":"377","author":"G Salles","year":"2011","unstructured":"Salles G, Seymour JF, Offner F, Lopez-Guillermo A, Belada D, Xerri L et al. Rituximab maintenance for 2 years in patients with high tumour burden follicular lymphoma responding to rituximab plus chemotherapy (PRIMA): a phase 3, randomised controlled trial. Lancet 2011; 377: 42\u201351.","journal-title":"Lancet"},{"key":"BFleu201395_CR36","doi-asserted-by":"publisher","first-page":"4003","DOI":"10.1182\/blood-2006-04-016725","volume":"108","author":"R Forstpointner","year":"2006","unstructured":"Forstpointner R, Unterhalt M, Dreyling M, Bock HP, Repp R, Wandt H et al. Maintenance therapy with rituximab leads to a significant prolongation of response duration after salvage therapy with a combination of rituximab, fludarabine, cyclophosphamide, and mitoxantrone (R-FCM) in patients with recurring and refractory follicular and mantle cell lymphomas: Results of a prospective randomized study of the German Low Grade Lymphoma Study Group (GLSG). Blood 2006; 108: 4003\u20134008.","journal-title":"Blood"},{"key":"BFleu201395_CR37","doi-asserted-by":"publisher","first-page":"1799","DOI":"10.1093\/jnci\/djr418","volume":"103","author":"L Vidal","year":"2011","unstructured":"Vidal L, Gafter-Gvili A, Salles G, Dreyling MH, Ghielmini M, Hsu Schmitz SF et al. Rituximab maintenance for the treatment of patients with follicular lymphoma: an updated systematic review and meta-analysis of randomized trials. J Natl Cancer Inst 2011; 103: 1799\u20131806.","journal-title":"J Natl Cancer Inst"},{"key":"BFleu201395_CR38","doi-asserted-by":"publisher","first-page":"3121","DOI":"10.1200\/JCO.2005.05.1003","volume":"24","author":"TM Habermann","year":"2006","unstructured":"Habermann TM, Weller EA, Morrison VA, Gascoyne RD, Cassileth PA, Cohn JB et al. Rituximab-CHOP versus CHOP alone or with maintenance rituximab in older patients with diffuse large B-cell lymphoma. J Clin Oncol 2006; 24: 3121\u20133127.","journal-title":"J Clin Oncol"},{"key":"BFleu201395_CR39","first-page":"8004","volume":"29","author":"C Gisselbrecht","year":"2011","unstructured":"Gisselbrecht C, Glass B, Laurent G, Gill DS, Linch MD, Trneny M et al. Maintenance with rituximab after autologous stem cell transplantation in relapsed patients with CD20 diffuse large B-cell lymphoma (DLBCL): CORAL final analysis. ASCO Meet Abstr 2011; 29: 8004.","journal-title":"ASCO Meet Abstr"},{"key":"BFleu201395_CR40","first-page":"8084","volume":"28","author":"YJ Li","year":"2010","unstructured":"Li YJ, Xia ZJ, Li S, Chen XQ, Xia Y, Xu F et al. Maintenance rituximab versus observation after R-CHOP or R-EPOCH in patients with untreated poor-prognosis diffuse large B-cell lymphoma and grade III follicular lymphoma. ASCO Meet Abstr 2010; 28: 8084.","journal-title":"ASCO Meet Abstr"},{"key":"BFleu201395_CR41","first-page":"7577","volume":"24","author":"EL Raefsky","year":"2006","unstructured":"Raefsky EL, Greco FA, Spigel DR, Doss HH, Farley C, Saez R et al. Brief duration rituximab(R)\/chemotherapy (CNOP or CVP) followed by maintenance rituximab in elderly\/poor performance status patients (pts) with diffuse large B-cell lymphoma (DLBCL): A phase II trial of the Minnie Pearl Cancer Research Network. ASCO Meet Abstr 2006; 24: 7577.","journal-title":"ASCO Meet Abstr"},{"key":"BFleu201395_CR42","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1093\/annonc\/mdr207","volume":"22","author":"N Fowler","year":"2011","unstructured":"Fowler N, Hagemeister F, McLaughlin P, Kwak L, Romaguera J, Fanale M et al. Lenalidomide plus rituximab is a highly effective and well-tolerated biologic therapy in untreated indolent B cell non-Hodgkin's lymphoma. Ann Oncol 2011; 22: 128\u2013129.","journal-title":"Ann Oncol"},{"key":"BFleu201395_CR43","first-page":"186","volume":"22","author":"M Dutia","year":"2011","unstructured":"Dutia M, Deroock I, Reed-Pease C, Tuscano J . Lenalidomide plus rituximab leads to a high rate of durable responses in patients with relapsed\/refractory indolent non-Hodgkin's lymphoma. Ann Oncol 2011; 22: 186\u2013186.","journal-title":"Ann Oncol"}],"container-title":["Leukemia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/leu201395.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/leu201395","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/leu201395.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,5,8]],"date-time":"2024-05-08T02:05:26Z","timestamp":1715133926000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/leu201395"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,4,2]]},"references-count":43,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2013,9]]}},"alternative-id":["BFleu201395"],"URL":"https:\/\/doi.org\/10.1038\/leu.2013.95","relation":{"has-review":[{"id-type":"doi","id":"10.3410\/f.718006480.793476367","asserted-by":"object"}]},"ISSN":["0887-6924","1476-5551"],"issn-type":[{"value":"0887-6924","type":"print"},{"value":"1476-5551","type":"electronic"}],"subject":[],"published":{"date-parts":[[2013,4,2]]},"assertion":[{"value":"5 February 2013","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 March 2013","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 April 2013","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Michael Wang, Sattva Neelapu, Larry Kwak and Nathan Fowler have received research support from Celgene Corporation in conducting the preclinical and clinical trials. Michael Wang has received honoraria for speaking on Celgene Corporation products. Nathan Fowler and Sattva Neelapu have consultant or advisory relationships with the Celgene Corporation.<b>Author Contributions<\/b>Michael Wang, Liang Zhang and Jorge Romaguera designed the study. Michael Wang, Nicolaus Wagner-Bartak, Fredrick Hagemeister, Sattva Neelapu, Peter McLaughlin, Anas Younes, Maria Badillo, Maria Bejarano and Yiming Chen collected and assembled the data. Michael Wang, Luis Fayad, Nicolaus Wagner-Bartak, Fredrick Hagemeister, Anas Younes, Jorge Romaguera, Larry Kwak, Richard Champlin, Ken H Young, Lei Feng, Luis Fayad, Michele Fanale, Nathan Fowler and Saatva Neelapu analyzed and interpreted the data. Michael Wang, Luis Fayad, Nicolaus Wagner-Bartak, Liang Zhang, Kate Newberry, Madhav Desai, Fredrick Hagemeister, Sattva Neelapu, Peter McLaughlin, Michelle Fanale, Anas Younes, Nathan Fowler, Ken H Young, Richard Champlin, Larry Kwak, Lei Feng, Maria Badillo, Maria Bejarano, Yiming Chen and Jorge Romaguera wrote the manuscript. Nathan Fowler, Jorge Romageura, Sattva Neelapu, Richard Champlin, Michelle Fanale, Yasuhiro Oki, Barbara Pro, Alma Rodriguez, Jatin Shah, Sheeba Thomas, Anas Younes and Fredrick Hagemeister provided study materials or patients. All authors approved the final manuscript.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}